This website uses cookies to enhance the user experience.
A

AKIGAI AS830 472 452

Research
Limited company
c/o Stig Nordal Hasselbakken 7 0851 OSLO, Norge

AKIGAI AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
3 years
since Dec 14, 2022
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
500,000
1 share class
Total number of shareholders
4
companies

Financials

Annual total result 2024
-6,095,129
NOK
Total equity 2024
4,629,771
NOK
Last update: May 22, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO
41.92 %
indirectly

Board

NameRoleShares
Chairman
41.92 %
indirectly
Board Member
41.92 %
indirectly
Board Member
14.83 %
indirectly
Board Member-

Others

NameRoleShares
S
STATEMENT AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Chairman
41.92 %
indirectly
Managing Director/CEO, Board Member
41.92 %
indirectly
Board Member
14.83 %
indirectly
-
1.14 %
indirectly
Last update: Dec 12, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
C
CAMERON INNOVATION AS
Ordinary shares
209,580
41.92 %
K
KERSTEN INNOVATION AS
Ordinary shares
209,580
41.92 %
F
FELDEN AS
Ordinary shares
79,840
15.97 %
T
TAXNOR AS
Ordinary shares
1,000
0.2 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year20242022
Total operating income
0
0
Annual Total Result
-6,095,129
-5,339,095
Total assets
5,381,494
1,932,612
Total liabilities
751,723
1,271,706
Total equity
4,629,771
660,905

P&L

Year20242022
Total operating income
0
0
Total operating costs
6,040,414
5,306,505
Operating result
-6,040,414
-5,306,505
Financial income/costs
-54,715
-32,590
Profit before tax
-6,095,129
-5,339,095
Total tax & extraordinary income/cost
0
0
Annual Total Result
-6,095,129
-5,339,095

Balance overview

Year20242022
Total fixed assets
1,670,182
853,671
Total current assets
3,711,312
1,078,941
Total assets
5,381,494
1,932,612
Short term debt
551,315
1,271,706
Long term debt
200,408
0
Total liabilities
751,723
1,271,706
Contributed capital
4,629,771
6,000,000
Retained earnings
0
-5,339,095
Total equity
4,629,771
660,905
Total equity and liabilities
5,381,494
1,932,612

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology